BRIDGEWATER, N.J.–(BUSINESS WIRE)– May 27, 2022 — Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the…Original Article
FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta
